Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy.

Although the trial-level AE signature association with survival varied, we observed a clear trend of longer survival times for patients receiving durvalumab treatment but not those receiving chemotherapy or placebo.

also in 12,136 other papers

We observed a slight trend for improved disease control rate in the PD-L1 <1% patient groups who were AE sig+ compared with AE sig– ( Figure S3 ).

also in 2,419 other papers